3DMed is a platform-based, biomarker-driven biopharmaceutical company in China, its mission is to develop safe and efficacious oncology products to fulfill unmet medical needs in China through collaborations with hospitals and clinicians. 3DMed’s platforms include the world largest PDC bank for liver cancer, Next-Generation DNA Sequencing, and bioinformatics for large genome data analysis. 3DMed is capable of conducting “clinical trials” in large number of human tumor celllines with clear genome information, thus identifying effective new compounds and discovering new biomarkers.
Prior to 3DMed, Dr. Gong served as VP of Drug Development and Regulatory Affairs of Beigene, CEO of BL Pharma, and CTO of JOINN Laboratories. From 1998 to 2008, Dr. Gong worked at US FDA as Reviewer, he conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics. Dr. Gong is member of the Drug Safety Evaluation Committee of the Chinese Pharmaceutical Association, Council member of AAALAC, and member of editorial board of Chinese Journal of New Drugs. Dr. Gong received his Ph.D. in Toxicology from New York University in 1996 and a medical degree from Beijing Medical College in 1984.